The Relationship between MMP-9 and Infarct Related Artery Reflow in Acute STEMI Patients
- *Corresponding Author:
- Fangming Guo
Department of Cardiology, YantaiShan Hospital, No.91 Jiefang Road
Yantai 264001, Shandong, P.R. China
E-mail: [email protected]
- Xiaohuan Wang
Department of Cardiology, Gansu Provincial Hospital, No. 204
Donggang West Road, Lanzhou City, 730000, P.R. China
E-mail: [email protected]
Received date: June 25, 2017; Accepted date: July 10, 2017; Published date: July 15, 2017
Citation: Guo F, Chai W, Liu M, Yu C, Liu W, et al. (2017) The Relationship between MMP-9 and Infarct Related Artery Reflow in Acute STEMI Patients. J Diabetes Metab 8:749. doi:10.4172/2155-6156.1000749
Copyright: © 2017 Guo F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Objective: Atherosclerotic plaque rupture leading to coronary artery occlusion is the culprit event which underpins a majority of acute myocardial infarction, and Matrix metalloproteinases (MMPs) contribute to atherosclerotic plaque rupture by involving in extracellular matrix degradation and artificial balloon extrusion. Patients with ST-segment elevation myocardial infarction (STEMI) caused by plaque rupture are at high risk for slow reflow, but the relationship between reflow and MMP-9 remains unclear, especially in the real world of local plaque rupture. We investigated the association between the levels of matrix metalloproteinase-9 (MMP-9) in infarct-related arterial infusion and the risk of slow reflow in STEMI patients following percutaneous coronary intervention (PCI).
Methods: 65 eligible acute STEMI patients undergoing successful PCI were included in the current study. Blood samples were obtained from the extraction catheter placed distal to the lesion during PCI. Plasma MMP-9 levels were determined by immunoassay method.
Results: Using multiple logistic regression analysis, MMP-9 levels (OR 0.881, CI 0.791-0.981; P=0.021) was found to be a significant risk factor of slow flow together with HSCORE (OR=0.085, CI 0.014-0.506; P=0.007). ROC curve with area under the curve (0.740) and 95% confidence interval (0.607-0.872) revealed that lesion MMP-9 changes had an predictive value for no reflow(P=0.002).
Conclusions: The present study indicated that plasma MMP-9 levels in the culprit coronary artery was associated with slow flow in patients with ST-elevation MI following successful primary PCI.